| Nicole Thompson, DO | |
|
239 Hurffville Crosskeys Rd Ste 460, Sewell, NJ 08080-4009 | |
| (856) 341-8181 | |
| Not Available |
| Full Name | Nicole Thompson |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 12 Years |
| Location | 239 Hurffville Crosskeys Rd Ste 460, Sewell, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083977862 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 25MB09634100 (New Jersey) | Secondary |
| 207R00000X | Internal Medicine | 25MB09634100 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Virtua West Jersey Hospitals | Voorhees, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Virtua Medical Group, Pa | 9830222397 | 1226 |
News Archive
New research asks if medicine is fast becoming a woman's domain. In the UK, female doctors are set to outnumber their male counterparts by 2017, a trend that British press headlines have dubbed "worrying" and "bad for medicine."
A University of Queensland researcher has been awarded $850,000 by one of Australia's largest private, charitable, medical foundations to develop ways to inhibit head and neck cancers, the fifth most common cancer worldwide.
Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.
University of Florida researchers say primitive cells that act like molecular maintenance men - traveling throughout the body to repair damaged blood vessels - become too rigid to move in patients with diabetes, fueling the disease's vascular complications.
› Verified 3 days ago
| Entity Name | Virtua Medical Group, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649226515 PECOS PAC ID: 9830222397 Enrollment ID: O20100804000338 |
News Archive
New research asks if medicine is fast becoming a woman's domain. In the UK, female doctors are set to outnumber their male counterparts by 2017, a trend that British press headlines have dubbed "worrying" and "bad for medicine."
A University of Queensland researcher has been awarded $850,000 by one of Australia's largest private, charitable, medical foundations to develop ways to inhibit head and neck cancers, the fifth most common cancer worldwide.
Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.
University of Florida researchers say primitive cells that act like molecular maintenance men - traveling throughout the body to repair damaged blood vessels - become too rigid to move in patients with diabetes, fueling the disease's vascular complications.
› Verified 3 days ago
| Entity Name | Kennedy Medical Group Practice, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952726796 PECOS PAC ID: 2860616877 Enrollment ID: O20140613000689 |
News Archive
New research asks if medicine is fast becoming a woman's domain. In the UK, female doctors are set to outnumber their male counterparts by 2017, a trend that British press headlines have dubbed "worrying" and "bad for medicine."
A University of Queensland researcher has been awarded $850,000 by one of Australia's largest private, charitable, medical foundations to develop ways to inhibit head and neck cancers, the fifth most common cancer worldwide.
Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.
University of Florida researchers say primitive cells that act like molecular maintenance men - traveling throughout the body to repair damaged blood vessels - become too rigid to move in patients with diabetes, fueling the disease's vascular complications.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nicole Thompson, DO 435 Hurffville Cross Keys Rd, Turnersville, NJ 08012-2453 Ph: (856) 218-5634 | Nicole Thompson, DO 239 Hurffville Crosskeys Rd Ste 460, Sewell, NJ 08080-4009 Ph: (856) 341-8181 |
News Archive
New research asks if medicine is fast becoming a woman's domain. In the UK, female doctors are set to outnumber their male counterparts by 2017, a trend that British press headlines have dubbed "worrying" and "bad for medicine."
A University of Queensland researcher has been awarded $850,000 by one of Australia's largest private, charitable, medical foundations to develop ways to inhibit head and neck cancers, the fifth most common cancer worldwide.
Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials.
University of Florida researchers say primitive cells that act like molecular maintenance men - traveling throughout the body to repair damaged blood vessels - become too rigid to move in patients with diabetes, fueling the disease's vascular complications.
› Verified 3 days ago
Dr. Janet Fontanella, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 211 County House Rd, Sewell, NJ 08080 Phone: 856-401-7660 | |
Dr. Lisa Carlene Dimedio, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 354 Hurffville Crosskeys Rd Bldg 2, Sewell, NJ 08080 Phone: 844-542-2273 | |
Dr. Anthony Pool Scarpaci, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 900 Medical Center Dr Ste 200, Sewell, NJ 08080 Phone: 856-557-7900 | |
Dr. Carlos A Obregon, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 100a Kings Way West, Sewell, NJ 08080 Phone: 856-218-8080 Fax: 856-218-8070 | |
Dr. Jennifer Megan Lecomte, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1474 Tanyard Road, Suite C100, Sewell, NJ 08080 Phone: 855-932-7476 Fax: 856-566-6300 | |
Dr. Sharan Parikh, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Plaza Dr Ste 103, Sewell, NJ 08080 Phone: 856-642-2133 Fax: 856-642-2134 | |
David Joseph Kovalsky, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 435 Hurfville-crosskeys Rd, Sewell, NJ 08012 Phone: 856-218-5634 Fax: 856-218-5664 |